How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

17,154 results for

Coronary Artery Bypass Graft

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Cost-effectiveness of coronary artery bypass grafting plus mitral valve repair versus coronary artery bypass grafting alone for moderate ischemic mitral regurgitation (Abstract)

Cost-effectiveness of coronary artery bypass grafting plus mitral valve repair versus coronary artery bypass grafting alone for moderate ischemic mitral regurgitation The Cardiothoracic Surgical Trials Network reported that left ventricular reverse remodeling at 2 years did not differ between patients with moderate ischemic mitral regurgitation randomized to coronary artery bypass grafting plus mitral valve repair (n = 150) or coronary artery bypass grafting alone (n = 151). To address health (...) bypass grafting plus mitral valve repair versus $51,326 for coronary artery bypass grafting alone (difference $8419; 95% uncertainty interval, 2259-18,757). Two-year costs were $81,263 versus $67,341 (difference 13,922 [2370 to 28,888]), and quality-adjusted life years were 1.35 versus 1.30 (difference 0.05; -0.04 to 0.14), resulting in an incremental cost-effectiveness ratio of $308,343/quality-adjusted life year for coronary artery bypass grafting plus mitral valve repair. At 10 years, its costs

2019 EvidenceUpdates

2. VEST external stent for coronary artery bypass grafts

of future cardiac events and the need for further interventions in people who have had CABG. Current NHS pathway There are 2 main revascularisation procedures used to treat coronary heart disease: CABG, and percutaneous coronary intervention (PCI). VEST external stent for coronary artery bypass grafts (MIB115) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 12The NICE guideline on stable angina recommends that both (...) VEST external stent for coronary artery bypass grafts VEST e VEST external stent for coronary artery b xternal stent for coronary artery bypass ypass gr grafts afts Medtech innovation briefing Published: 2 August 2017 nice.org.uk/guidance/mib115 pathways Summary Summary The technology technology described in this briefing is the venous external support, or VEST, a kink- resistant external stent for saphenous vein grafts used during coronary artery bypass graft (CABG) surgery. The inno innovativ

2017 National Institute for Health and Clinical Excellence - Advice

4. Randomised controlled trial: Percutaneous coronary intervention has similar 5-year survival rates to coronary artery bypass grafting surgery for patients with unprotected left main artery disease

Randomised controlled trial: Percutaneous coronary intervention has similar 5-year survival rates to coronary artery bypass grafting surgery for patients with unprotected left main artery disease Percutaneous coronary intervention has similar 5-year survival rates to coronary artery bypass grafting surgery for patients with unprotected left main artery disease | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage (...) intervention has similar 5-year survival rates to coronary artery bypass grafting surgery for patients with unprotected left main artery disease Article Text Therapeutics/Prevention Randomised controlled trial Percutaneous coronary intervention has similar 5-year survival rates to coronary artery bypass grafting surgery for patients with unprotected left main artery disease Carlos Collet 1 , Patrick W Serruys 2 Statistics from Altmetric.com Commentary on: Mäkikallio T, Holm NR, Lindsay M, et al

2017 Evidence-Based Medicine

5. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. (Abstract)

Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. The Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) trial was a non-inferiority trial that compared percutaneous coronary intervention (PCI) using first-generation paclitaxel-eluting stents with coronary artery bypass grafting (CABG) in patients with de-novo three-vessel (...) , acute myocardial infarction, or an indication for concomitant cardiac surgery were excluded. The primary endpoint of the SYNTAXES study was 10-year all-cause death, which was assessed according to the intention-to-treat principle. Prespecified subgroup analyses were performed according to the presence or absence of left main coronary artery disease and diabetes, and according to coronary complexity defined by core laboratory SYNTAX score tertiles. This study is registered with ClinicalTrials.gov

2019 Lancet

6. Sequential multidetector computed tomography assessments after venous graft treatment solution in coronary artery bypass grafting

management software Create file Cancel Actions Cite Share Permalink Copy Page navigation J Thorac Cardiovasc Surg Actions . 2019 Nov 9;S0022-5223(19)32503-6. doi: 10.1016/j.jtcvs.2019.10.115. Online ahead of print. Sequential Multidetector Computed Tomography Assessments After Venous Graft Treatment Solution in Coronary Artery Bypass Grafting , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Surgery, Montreal Heart Institute, Montréal, Québec, Canada. Electronic address (...) , New Brunswick, Canada. 9 Montreal Health Innovations Coordinating Center, Montreal, Québec, Canada. 10 Somahlution, Jupiter, Fla. 11 Department of Cardiovascular Surgery, Charité Universitätsmedizin Berlin, Berlin, Germany; Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany. PMID: 31866081 DOI: Item in Clipboard Sequential Multidetector Computed Tomography Assessments After Venous Graft Treatment Solution in Coronary Artery Bypass Grafting Louis P

2020 EvidenceUpdates

7. The no-touch saphenous vein is an excellent alternative conduit to the radial artery 8 years after coronary artery bypass grafting: A randomized trial

The no-touch saphenous vein is an excellent alternative conduit to the radial artery 8 years after coronary artery bypass grafting: A randomized trial The No-Touch Saphenous Vein Is an Excellent Alternative Conduit to the Radial Artery 8 Years After Coronary Artery Bypass Grafting: A Randomized Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search (...) : Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation J Thorac Cardiovasc Surg Actions . 2019 Oct 26;S0022-5223(19)32357-8. doi: 10.1016/j.jtcvs.2019.09.177. Online ahead of print. The No-Touch Saphenous Vein Is an Excellent Alternative Conduit to the Radial Artery 8 Years After Coronary Artery Bypass Grafting: A Randomized Trial , , , , , Affiliations Expand Affiliations 1 Faculty of Medicine and Health, Department

2020 EvidenceUpdates

8. L-carnitine supplementation in the recovery of plasma L-carnitine in patients with heart failure submitted to coronary artery bypass grafting. Full Text available with Trip Pro

L-carnitine supplementation in the recovery of plasma L-carnitine in patients with heart failure submitted to coronary artery bypass grafting. Coronary artery bypass grafting reduces plasma L-carnitine and may impair the production of myocardial energy. L-carnitine supplementation may elevate plasma L-carnitine and increase cardiac mechanical efficiency. The objective of this study was to verify the recovery of preoperative plasma LC in patients with heart failure undergoing coronary artery (...) postoperative day, there was a reduction in plasma L-carnitine in groups A (17.4%) and B (14.4%). In the comparison between the groups, plasma L-carnitine was higher in group A than B in 10º (p = 0.024), 30º (p = 0.001), and 60º postoperative day (p = 0.008). Supplementation of L-carnitine at a daily oral dose of 50 mg / kg in patients with heart failure undergoing coronary artery bypass grafting may recover preoperative plasma L-carnitine within 10 days.

2019 Anais da Academia Brasileira de Ciencias Controlled trial quality: uncertain

9. Association between incidence of atrial fibrillation and duration of cardiopulmonary bypass in coronary artery bypass graft surgery (CABG): a cohort study Full Text available with Trip Pro

Association between incidence of atrial fibrillation and duration of cardiopulmonary bypass in coronary artery bypass graft surgery (CABG): a cohort study Open heart surgery is one of the most common and valuable treatment methods for cardiovascular diseases, a common side effect of which is atrial fibrillation that occurs due to various reasons.To determine the relationship between incidence of atrial fibrillation (AF) and duration of cardiopulmonary bypass (CPB) in patients after open heart (...) surgery.The present retrospective cohort study was conducted on 330 patients in Farshchian Heart Center through census. The required data were collected from medical records of the patients undergoing coronary bypass surgery using data collection between April 2015 and March 2015. Then, data analysis was performed using SPSS software (ver.16) at error level of p<0.05. The tests used in this study included independent-samples t-test, Mann-Whitney, and chi-squared tests.Based on the results, mean age

2018 Electronic physician

10. Effect of Remote Ischaemic preconditioning on Clinical outcomes in patients undergoing Coronary Artery bypass graft surgery (ERICCA study): a multicentre double-blind randomised controlled clinical trial Full Text available with Trip Pro

Effect of Remote Ischaemic preconditioning on Clinical outcomes in patients undergoing Coronary Artery bypass graft surgery (ERICCA study): a multicentre double-blind randomised controlled clinical trial Effect of Remote Ischaemic preconditioning on Clinical outcomes in patients undergoing Coronary Artery bypass graft surgery (ERICCA study): a multicentre double-blind randomised controlled clinical trial Journals Library An error occurred retrieving content to display, please try again (...) 3 National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore 4 Cardiovascular and Metabolic Disorders Program, Duke–National University of Singapore, Singapore 5 Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK 6 Department of Cardiothoracic Surgery, Papworth Hospital, Cambridge, UK 7 The Heart Hospital, University College London Hospitals NHS Foundation Trust, London, UK 8 Department of Anaesthetics and Pain Therapy, King’s College

2016 NIHR HTA programme

11. Pulmonary artery hypertension following coronary artery bypass grafting: a case report Full Text available with Trip Pro

Pulmonary artery hypertension following coronary artery bypass grafting: a case report Post-operative pulmonary complications in coronary artery bypass grafting (CABG) surgery are mostly reversible. We report a patient who developed pulmonary arterial hypertension (PAH) post-CABG and did not have pulmonary hypertension prior to surgery. PAH Group 1 was diagnosed after right and left heart catheterization. To the best of our knowledge, this is the only reported case of a patient developing PAH (...) post-CABG surgery. This could be explained by immunological and/or haemostatic changes triggered by cardiopulmonary bypass. We hope that as more knowledge is gained regarding the pathophysiology of PAH, cases like these could be better understood.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure

12. Outcomes following surgical revascularization with single versus bilateral internal thoracic arterial grafts in patients with left main coronary artery disease undergoing coronary artery bypass grafting: insights from the EXCEL trial. (Abstract)

Outcomes following surgical revascularization with single versus bilateral internal thoracic arterial grafts in patients with left main coronary artery disease undergoing coronary artery bypass grafting: insights from the EXCEL trial. Observational data suggest that the use of a single internal thoracic artery (SITA) may result in inferior outcomes compared with bilateral internal thoracic artery (BITA) use for coronary artery bypass grafting (CABG)-a finding not yet supported by randomized (...) trial outcomes. However, the optimal number of internal thoracic artery grafts in patients with left main coronary artery disease has not been investigated.The EXCEL trial randomized 1905 patients with left main coronary artery disease to percutaneous coronary intervention with everolimus-eluting stents versus CABG. Among the 905 patients undergoing CABG, 688 (76.0%) received SITA and 217 (24.0%) received BITA. Differences in clinical event rates were estimated using the Kaplan-Meier method

2018 European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery Controlled trial quality: predicted high

13. Coronary Artery Bypass Grafting with Arterial Grafts in Patients with Kawasaki Disease Affecting the Coronary Artery: a Korean Single-Center Study Full Text available with Trip Pro

Coronary Artery Bypass Grafting with Arterial Grafts in Patients with Kawasaki Disease Affecting the Coronary Artery: a Korean Single-Center Study This study aimed to review the long-term clinical outcomes and graft patency of coronary artery bypass grafting (CABG) using arterial grafts in patients with Kawasaki disease (KD) affecting the coronary artery.Twenty patients with KD who underwent CABG from January 2002 to June 2014 were enrolled. There were 4 male (20%) and 16 female (80%) patients (...) with ages at operation ranging from 2 to 42 years (median, 17.5 years). Our routine operative strategy was off-pump CABG with arterial grafts. The mean follow-up duration was 59.5 ± 48.5 months (range, 1-159 months). Coronary angiogram or computed tomography angiogram was used to evaluate graft patency in 16 patients (80%).All patients survived CABG without late mortality. Left internal thoracic arteries were used in 19 patients, while right internal thoracic arteries were used in 10 patients. Right

2018 Journal of Korean medical science

14. Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial. The effect of ticagrelor with or without aspirin on saphenous vein graft patency in patients undergoing coronary artery bypass grafting (CABG) is unknown.To compare the effect of ticagrelor + aspirin or ticagrelor alone vs aspirin alone on saphenous vein graft patency 1 year after CABG.Randomized, multicenter, open-label (...) mg twice daily) + aspirin (100 mg once daily) (n = 168), ticagrelor (90 mg twice daily) (n = 166), or aspirin (100 mg once daily) (n = 166) within 24 hours post-CABG. Neither patients nor treating physicians were blinded to allocation.Primary outcome was saphenous vein graft patency 1 year after CABG (FitzGibbon grade A) adjudicated independently by a committee blinded to allocation. Saphenous vein graft patency was assessed by multislice computed tomographic angiography or coronary

2018 JAMA Controlled trial quality: predicted high

15. Comparison of Outcomes After Transcatheter vs Surgical Aortic Valve Replacement Among Patients at Intermediate Operative Risk With a History of Coronary Artery Bypass Graft Surgery: A Post Hoc Analysis of the SURTAVI Randomized Clinical Trial. (Abstract)

Comparison of Outcomes After Transcatheter vs Surgical Aortic Valve Replacement Among Patients at Intermediate Operative Risk With a History of Coronary Artery Bypass Graft Surgery: A Post Hoc Analysis of the SURTAVI Randomized Clinical Trial. Surgical aortic valve replacement (SAVR) has increased risk for patients with aortic stenosis (AS) and a history of coronary artery bypass graft (CABG) surgery. Transcatheter aortic valve replacement (TAVR) may be an alternative.To compare TAVR with SAVR

2019 JAMA cardiology Controlled trial quality: predicted high

16. Endoscopic saphenous vein harvest for coronary artery bypass grafting (IPG494)

saphenous vein harvest for coronary artery bypass grafting in June 2014. This document replaces previous guidance on endoscopic saphenous vein harvest for coronary artery bypass grafting (NICE interventional procedure guidance 343, May 2010). Description Coronary artery disease (CAD) refers to hardening and narrowing of the coronary arteries as a result of atherosclerosis. This can cause angina and myocardial infarction and result in heart failure. One of the treatment options for suitable patients (...) Endoscopic saphenous vein harvest for coronary artery bypass grafting (IPG494) Overview | Endoscopic saphenous vein harvest for coronary artery bypass grafting | Guidance | NICE Endoscopic saphenous vein harvest for coronary artery bypass grafting Interventional procedures guidance [IPG494] Published date: June 2014 Share Save Guidance The National Institute for Health and Care Excellence (NICE) issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Endoscopic

2014 National Institute for Health and Clinical Excellence - Interventional Procedures

17. Clinical outcomes of patients with multivessel coronary artery disease treated with robot-assisted coronary artery bypass graft surgery versus one-stage percutaneous coronary intervention using drug-eluting stents. Full Text available with Trip Pro

Clinical outcomes of patients with multivessel coronary artery disease treated with robot-assisted coronary artery bypass graft surgery versus one-stage percutaneous coronary intervention using drug-eluting stents. A number of studies have reported on treatment outcomes of coronary stenting (PCI) for multivessel coronary artery diseases (MVD), and compared them with the conventional coronary artery bypass grafting (CABG). However, the clinical outcomes of robot-assisted CABG (R-CABG (...) %, P = .751). The residual stenosis was 4.1 ± 4.4 in the R-CABG group, and comparably 3.5 ± 3.7 in the PCI group (P = .077). Patients in the R-CABG group were younger, with more severe coronary artery disease (CAD) and had more background risk factors. The in-hospital and long-term mortalities as well as the incidence of TLR, myocardial infarction (MI), stroke were all similar between groups. But the incidence of TVR and any revascularization were lower in the R-CABG group. The long-term mortality

2019 Medicine

18. Radial-Artery or Saphenous-Vein Grafts in Coronary-Artery Bypass Surgery. Full Text available with Trip Pro

Radial-Artery or Saphenous-Vein Grafts in Coronary-Artery Bypass Surgery. The use of radial-artery grafts for coronary-artery bypass grafting (CABG) may result in better postoperative outcomes than the use of saphenous-vein grafts. However, randomized, controlled trials comparing radial-artery grafts and saphenous-vein grafts have been individually underpowered to detect differences in clinical outcomes. We performed a patient-level combined analysis of randomized, controlled trials to compare (...) ) follow-up time of 60±30 months, the incidence of adverse cardiac events was significantly lower in association with radial-artery grafts than with saphenous-vein grafts (hazard ratio, 0.67; 95% confidence interval [CI], 0.49 to 0.90; P=0.01). At follow-up angiography (mean follow-up, 50±30 months), the use of radial-artery grafts was also associated with a significantly lower risk of occlusion (hazard ratio, 0.44; 95% CI, 0.28 to 0.70; P<0.001). As compared with the use of saphenous-vein grafts

2018 NEJM

19. Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass: The LICORN Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass: The LICORN Randomized Clinical Trial. Low cardiac output syndrome after cardiac surgery is associated with high morbidity and mortality in patients with impaired left ventricular function.To assess the ability of preoperative levosimendan to prevent postoperative low cardiac output syndrome.Randomized, double-blind, placebo (...) -controlled trial conducted in 13 French cardiac surgical centers. Patients with a left ventricular ejection fraction less than or equal to 40% and scheduled for isolated or combined coronary artery bypass grafting with cardiopulmonary bypass were enrolled from June 2013 until May 2015 and followed during 6 months (last follow-up, November 30, 2015).Patients were assigned to a 24-hour infusion of levosimendan 0.1 µg/kg/min (n = 167) or placebo (n = 168) initiated after anesthetic induction.Composite end

2017 JAMA Controlled trial quality: predicted high

20. Heartcel for heart failure in patients at risk of incomplete revascularisation following coronary artery bypass graft

Heartcel for heart failure in patients at risk of incomplete revascularisation following coronary artery bypass graft Heartcel for heart failure in patients at risk of incomplete revascularisation following coronary artery bypass graft Heartcel for heart failure in patients at risk of incomplete revascularisation following coronary artery bypass graft NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation NIHR HSRIC. Heartcel for heart failure in patients at risk of incomplete revascularisation following coronary artery bypass graft. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' objectives Heart failure is a common and disabling condition that affects the heart's ability to pump blood around the body. It is often caused by coronary artery disease, which happens when there is a build-up of fatty

2016 Health Technology Assessment (HTA) Database.

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>